Although there is much evidence for a role of the inhibitory neurotransmitter g-aminobutyric acid (GABA) in the pathophysiology of anxiety and depression, the role of GABA B receptors in behavioral processes related to these disorders has not yet been fully established. GABA B receptors are G-protein-coupled receptors, which act as functional heterodimers made up of GABA B(1) and GABA B(2) subunits. Using recently generated GABA B(1) À/À mice, which lack functional GABA B receptors, and pharmacological tools we assessed the role of GABA B receptors in anxiety-and antidepressant-related behaviors. In the light-dark box, GABA B(1) À/À mice were more anxious than their wild-type littermates (less time spent in the light; reduced number of transitions). GABA B(1) À/À mice were also more anxious in the staircase test. Conversely, acute and chronic treatment with GS39783, a novel GABA B receptor positive modulator, decreased anxiety in the light-dark box and elevated zero maze tests for anxiety. On the other hand, GABA B(1) À/À mice had decreased immobility (antidepressant-like behavior) in the forced swim test (FST). These behavioral effects are unrelated to alterations in locomotor activity. In confirmation of the genetic data, acute and chronic treatment with CGP56433A, a selective GABA B receptor antagonist, also decreased immobility in the FST, whereas GS39783 did not alter this behavior. Taken together, these data suggest that positive modulation of the GABA B receptor may serve as a novel therapeutic strategy for the development of anxiolytics, whereas GABA B receptor antagonism may serve as a basis for the generation of novel antidepressants.